Chemoradiotherapy plus immunotherapy may expand checkpoint blockade benefit in mismatch repair-proficient rectal cancer

◇ RESEARCH

Adding immune checkpoint blockade to chemoradiotherapy has been associated with pathological complete response rates of 30% or more in pMMR rectal cancer trials, higher than expected with chemoradiotherapy alone, though long-term disease control data remain early endpoints. (Ann Gastroenterol Surg)